The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia

International Clinical Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 83-90

  Hwang, Samuel Suk Hyun ^a,b   Jung, Dong Chung ^c   Ahn, Yong Min ^a,c   Kim, Se Hyun ^a   Kim, Yong Sik ^a,b,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Liverpool University Neuroleptic Side Effects Rating Scale; Nocebo effect; Psychopathology; Red herring; Schizophrenia; Subjective side effects

Indexed keywords

AMISULPRIDE; OLANZAPINE;

ADULT; ANXIETY DISORDER; ARTICLE; DEPRESSION; DISEASE SEVERITY; FEMALE; HUMAN; LIVERPOOL UNIVERSITY NEUROLEPTIC SIDE EFFECTS RATING SCALE; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SELF CONCEPT; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; ANXIETY; BENZODIAZEPINES; COGNITION DISORDERS; DEPRESSIVE DISORDER; FEMALE; HUMANS; LINEAR MODELS; MALE; MODELS, PSYCHOLOGICAL; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE;

EID: 76349095756     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328334e5a8     Document Type: Article

References (43)

1. Ahn YM, Koh KB, Koo YJ, Kim L, Min KJ, Park KC, et al. (2002a). The study for switching methods to olanzapine in Korean schizophrenic patients treated with other antipsychotics: (I)-comparison of therapeutic efficacy. J Korean Neuropsychiatr Assoc 41:876-889.
2. Ahn YM, Kweon YS, Kwon JS, Min SH, Park DB, Yang MJ, et al. (2002b). The Study for wwitching methods to olanzapine in Korean schizophrenic patients treated with other antipsychotics: (I)-comparison of safety. J Korean Neuropsychiatr Assoc 41:890-904.
3. Ahn YM, Lee KY, Kim C-E, Kim J-J, Kang D-Y, Jun T-Y, et al. (2009). Changes in neurocognitive function in schizophrenia patients after starting or switching to amisulpride in comparison with the normal controls. J Clin Psychpharmacol 29:117-123.
4. Awad AG, Voruganti LN (2000). Intervention research in psychosis: issues related to the assessment of quality of life. Schizophr Bull 26:557-564.
5. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
6. Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002). Nonspecific medication side effects and the nocebo phenomenon. JAMA 287:622-627.
7. Bebbington PE, Angermeyer M, Azorin JM, Marwaha S, Marteau F, Toumi M (2009). Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Suppl 438:22-28.
8. Bell M, Fiszdon J, Richardson R, Lysaker P, Bryson G (2007). Are self-reports valid for schizophrenia patients with poor insight? Relationship of unaware-ness of illness to psychological self-report instruments. Psychiatry Res 151:37-46.
9. Benedetti F, Amanzio M, Vighetti S, Asteggiano G (2006). The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. J Neurosci 26:12014-12022.
10. Bentler PM (1990). Comparative fit indexes in structural models. Psychol Bull 107:238-246.
11. Cabeza IG, Amador MS, López CA, González de Chávez M (2000). Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 41:349-355.
12. Carrick R, Mitchell A, Powell RA, Lloyd K (2004). The quest for well-being: a qualitative study of the experience of taking antipsychotic medication. Psychol Psychother 77:19-33.
13. Coukell AJ, Spencer CM, Benfield P (1996). Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 6:237-256. (Pubitemid 26306854)
14. Davis C, Ralevski E, Kennedy SH, Neitzert CS (1995). The role of personality factors in the reporting of side effect complaints to moclobemide and placebo. J Clin Psychopharmacol 15:347-352.
15. Day JC, Wood G, Dewey M, Bentall RP (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry 166:650-653.
16. Day JC, Bentall RP, Roberts C, Randall F, Rogers A, Cattell D, et al. (2005). Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 62:717-724.
17. De Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L (2002). Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology (Berl) 162:24-28.
18. Foster JM, van der Molen T, Caeser M, Hannaford P (2008). The use of questionnaires for measuring patient-reported side effects of drugs: its importance and methodological challenges. Pharmacoepidemiol Drug Saf 17:278-296.
19. Fountoulakis KN, Iacovides A, Kaprinis SG, Kaprinis GS (2003). Diffuse muscle pain with quetiapine. Br J Psychiat 182:81.
20. Hogan TP, Awad AG (1992). Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22:347-352.
21. Hogan TP, Awad AG, Eastwood R (1983). A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13:177-183.
22. Hwang SS, Chang JS, Lee KY, Ahn YM, Kim YS (2009). The causal model of insight in schizophrenia based on the positive and negative syndrome scale factors and the structural equation modeling. J Nerv Ment Dis 197:79-84.
23. Jung HY, Joo YH, Shin HK, Chung EK, Kang UG, Roh MS, et al. (2002). A validation study of Korean-version of Liverpool University neuroleptic side effect rating scale (LUNSERS). J Korean Neuropsychiatr Assoc 41:138-145.
24. Jung HY, Kim JH, Ahn YM, Kim SC, Hwang SS, Kim YS (2005). Liverpool university neuroleptic side-effect rating scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia. Hum Psychopharmacol 20:41-45.
25. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
26. Kim JH, Lee BC, Park HJ, Ahn YM, Kang UG, Kim YS (2002). Subjective emotional experience and cognitive impairment in drug-induced akathisia. Comp Psychiatry 43:456-462.
27. Lambert TJ, Cock N, Alcock SJ, Kelly DL, Conley RR (2003). Measurement of antipsychotic-induced side effects: support for the validity of a self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Hum Psychopharmacol 18:405-511.
28. Lee KH, Harris AW, Loughland CM, Williams LM (2003). The five symptom dimensions and depression in schizophrenia. Psychopathology 36:226-233.
29. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161:1-56.
30. Lincoln TM, Lüllmann E, Rief W (2007). Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review. Schizophr Bull 33:1324-1342.
31. Lindenmayer JP, Bernstein-Hyman R, Grochowski S (1994). A new five factor model of schizophrenia. Psychiatr Q 65:299-322.
32. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987). The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334:1-100.
33. McLoughlin C, Elliott P, McCarthy G, Mirakhur RK (1992). Muscle pains and biochemical changes following suxamethonium administration after six pretreatment regimens. Anaesthesia 47:202-206.
34. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. (2001). Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 50:79-88. (Pubitemid 32510889)
35. Naber D, Karow A, Lambert M (2005). Subjective well-being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl 427:29-34.
36. Reeves RR, Ladner ME, Hart RH, Burke RS (2007). Nocebo effects with antidepressant clinical drug trial placebos. Gen Hosp Psychiatry 29:275-277.
37. Ritsner M, Perelroyzen G, Ilan H, Gibel A (2004). Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 24:245-254.
38. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
39. Ullman JB (2006). Structural equation modeling: reviewing the basics and moving forward. J Pers Assess 87:35-50.
40. Vorunganti LP, Baker LK, Awad AG (2008). New generation antipsychotic drugs and compliance behaviour. Curr Opin Psychiatry 21:133-139.
41. Williamson A (2007). Using self-report measures in neurobehavioural toxicology: can they be trusted? Neurotoxicology 28:227-234.
42. Yi JS, Ahn YM, Shin HK (2001). Reliability and validity of the Korean version of the positive and negative syndrome scale. J Korean Neuropsychiatr Assoc 40:1090-1105.
43. Yilmaz Y, Tasdemir HA, Paksu MS (2009). The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity. Eur J Paediatr Neurol 13:439-443.